id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-1936	Reich, Kristian; Kristensen, Lars Erik; Smith, Saxon D. ; Rich, Phoebe; Sapin, Christophe; Liu Leage, Soyi; McKenzie, Robert; Schuster, Christopher; Riedl, Elisabeth; Gooderham, Melinda	Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial	2022	12	.pdf	application/pdf	6470	426	61	IXE- versus ADA- treated patients had more rapid PASI75 responses with a sig- nificantly higher proportion achieving PASI75 from W4 to W16, and numerically, but not significantly (except for W40), more patients achieving PASI75 through W52 (Figure 3C). Objectives: This analysis investigated efficacy and safety of ixekizumab and adalimumab in the sub- group of patients with PsA and moderate-to-severe PsO through W52.	cache/dpc-1936.pdf	txt/dpc-1936.txt